UCL HUNTINGTON’S DISEASE RESEARCH

INFORMATION FOR SCIENTISTS, CLINICIANS, PATIENTS, RELATIVES AND CARERS

HD Natural History Study

At a glance

 Now recruiting
 Involves blood tests
Scan Magnetic Resonance Imaging
 HD core research assessments
 Smart phone and smart watch monitoring
 Questionnaires
 Option to receive trial drug at end of study
 CSF donation (optional)

About this study

The HD Natural History Study will monitor people over a period of 16 months who have early manifest HD by testing their symptoms and measuring their mutant huntingtin levels over time.

What is involved?

The study will last for 16 months and includes an initial screening visit to determine eligibility. For eligible participants a further 4 clinic visits will take place with lumbar punctures, MRI brain scans, blood tests, physiological and neurological examinations and vital sign measurements. Participants will also be required to complete daily assessments using a smart phone and smart watch. These can be done at home.

After study participation, eligible participants will be offered to join a Roche-sponsored study of an experimental drug called RG6042 which is being tested for the treatment of HD.

Who can take part?

Patients with early stage HD may be eligible to take part. Eligibility will be determined by a doctor.

 

https://clinicaltrials.gov/ct2/show/NCT03664804?term=Roche&cond=Huntington+Disease&rank=1
Updated February 1, 2019